Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 7,730

Document Document Title
WO/2011/089932A1
A process for producing zinc toluenesulfonate comprising reacting a zinc compound comprising Zn(OH)2 with toluenesulfonic acid and/or a salt thereof in the presence of an alcohol having 1 to 20 carbon atoms in total at a temperature high...  
WO/2011/083304A1
The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the a...  
WO/2011/080562A1
The present invention relates to novel aza-peptides containing 2,2-disubstituted 5 cyclobutyl and/or substituted alkoxy benzyl derivatives of formula (I) and compositions for inhibiting Human Immunodeficiency Virus (HIV) and process for ...  
WO/2011/078101A1
Provided is an adamantanamine derivative useful as an important intermediate for a 11βHSD-1 inhibitor. The adamantanamine derivative is represented by general formula (II) [wherein R10 is a group represented by the general formula: -(CR...  
WO/2011/078000A1
A method for treating an isocyanate residue, which comprises carrying out a thermal decomposition reaction of a carbamate that is produced by the reaction among an amine, urea and/or an N-unsubstituted carbamic acid ester and an alcohol ...  
WO/2011/073362A1
A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmet...  
WO/2011/070585A1
Processes for preparing Rivastigmine, salts and intermediates thereof are disclosed. More specifically, a process for preparing S-(-)-3-[(l -dimethylamino)ethyl]-phenol is provided.  
WO/2011/070539A1
Compounds of Formula (II) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C...  
WO/2011/067266A1
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2011/067183A2
The invention relates to an N-allyl carbamate compound suitable as an additive, the chemical main body thereof allowing modifications of the overall structure of the compound in order to ensure sufficient compatibility with as many binde...  
WO/2011/062139A1
Provided is a three-step method for manufacturing optically active 3-tert-butoxycarbonylamino-2-fluoro-1-propanol. The provided method can dramatically reduce the amount of a palladium catalyst used and can complete the reaction in one c...  
WO/2011/061675A1
The present invention provides a process for the preparation of N-[(1S)-3-nitro-2oxo- l-(phenylmethyl)propyl]carbamic acid, 1,1-dimethylethyl ester (Nitroketone) of formula I, comprising the steps of, (a) preparing a solution of N- (tert...  
WO/2011/057986A1
This invention relates to homoglutamic acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions...  
WO/2011/054171A1
Tyrosine derivative histone deacetylases inhibitors and preparation methods and applications thereof are disclosed. A kind of powerful histone deacetylases inhibitors, which can effectively treat the diseases of abnormal expression of th...  
WO/2011/054818A2
The invention relates to a novel non-crystallizing methacrylate and a method for the production thereof. The invention further relates to a photopolymer formulation comprising the methacrylate of the invention as well as to use of said p...  
WO/2011/048727A1
Provided is a ruthenium carbonyl complex represented by general formula (1). (1) RuXY(CO)(L) (In general formula (1), X and Y represent anionic ligands and may be the same as each other or different from each other; and L represents a tr...  
WO/2011/046082A1
Provided is an oxime ether derivative represented by formula (I), or a salt thereof. (1) (In the formula, X represents a halogen atom, an alkyl group, or the like; Y represents an oxygen atom or the like; Z represents an oxygen atom or t...  
WO/2011/046007A1
Provided is a process for preparing easily and efficiently an intermediate compound for use in the synthesis of a gadolinium complex which has a substituent capable of improving retention in blood or organ specificity. Also provided is a...  
WO/2011/039781A1
The invention relates to improved processes for the preparation of lacosamide. The invention also relates to a novel intermediate useful in the preparation of lacosamide. The invention also relates to process for the purification of laco...  
WO/2011/037613A1
The present invention relates to salts of 2-(2-((4-(((4-chlorophenyl)(phenyl)-carbamoyloxy)methyl)cycl ohexyl)methoxy)acetamido)ethanesulfonic acid (Compound 1) and crystalline forms, solvates and hydrates thereof. The present invention ...  
WO/2011/037818A1
The present disclosure is directed to a sag control agent comprising a reaction product of an isocyanate and a fluorinated amine. This disclosure is further directed to a coating composition comprising the sag control agent. This disclos...  
WO/2011/034078A1
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...  
WO/2011/026781A1
The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formula (1) in medicine.  
WO/2011/023757A1
A process for preparing iodopropargyl compounds of the formula (I) in which R is hydrogen, in each case optionally substituted C1-C20-alkyl, C2-C20-alkenyl, C6-C20-aryl or C3-C20-cycloalkyl, and n is an integer from 1 to 6, characterized...  
WO/2011/026144A1
Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and syste...  
WO/2011/021257A1
Provided is a method for producing an N-substituted carbamic acid ester derived from an organic amine from an organic amine, a carbonic acid derivative, and a hydroxy compound containing one or more hydroxy compounds. The method comprise...  
WO/2011/022457A1
Compounds comprising a lactam moiety, and a urethane or urea functional group are presented. By a preferred synthesis route, they are prepared using at least one polymerizable compound comprising an isocyanate moiety and reacting it with...  
WO/2011/021258A1
Provided is a process for the preparation of an N-substituted carbamic acid O-aryl ester derived from a ureido-containing compound. The process comprises a step of preparing an N-substituted carbamic acid O-aryl ester from both a ureido ...  
WO/2011/021397A1
Provided are 4-modified colchicine compounds and medicines using the same. Specifically provided are colchicine derivatives represented by general formula (1), salts thereof, and solvates of the same. In general formula (1), R1 is a halo...  
WO/2011/012659A2
Disclosed are diethyl 4-(4-fluorobenzylamino)-l,2-phenylenedicarbamate (IV) and salts thereof, which are useful as reference markers and reference standards for analyzing samples comprising retigabine or salts thereof. Also disclosed is ...  
WO/2011/006621A1
This invention relates to novel cyclo alkyl compounds suitable for labeling by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, ...  
WO/2011/005322A2
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for det...  
WO/2011/005959A1
Compounds useful in the preparation of telavancin, for example, were prepared. These compounds include decylaminoethanal dialkyl acetals and N-protected decylaminoethanal dialkyl acetals, imidazolidine derivatives, and N-protected- decyl...  
WO/2010/150205A1
Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides which are useful for being biologically and pharmacologically screened, an...  
WO/2010/143409A1
Disclosed are: a process for producing a salt of an optically active thiazolylalanine derivative which has a desired configuration by converting a thiazolylalanine derivative into a salt thereof and crystallizing a compound having one of...  
WO/2010/144371A1
The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.  
WO/2010/131962A2
The present invention concerns new thiolysine and selenolysine compounds that can be used as building blocks for peptides and proteins, providing ligation handles for site-and chemoselective modification of said peptides and proteins. In...  
WO/2010/122682A1
High-quality N-alkoxycarbonyl-tert-leucines can be efficiently and stably produced via simple operation by reacting tert-leucine with an N-alkoxycarbonylating agent in an amount of 0.90 to 1.00 time by mole that of tert-leucine in the pr...  
WO/2010/117796A2
The present disclosure provides compositions and methods for the preparation of ? chloroketones from carboxylic acids. In particular embodiments, the present disclosure provides procedures for the preparation of chiral ? chloroketone der...  
WO/2010/116871A1
Disclosed is a process for producing an urethane compound, which comprises reacting a primary amine, urea and/or an N-unsubstituted carbamic acid ester and an alcohol with one another in the presence of a catalyst comprising a first meta...  
WO/2010/113458A1
Disclosed is a commercially advantageous method for manufacturing a 1,5-benzodiazepine compound. A compound (5) is obtained from a reaction formula and used as an intermediate.  
WO/2010/113939A1
Disclosed are a compound which has excellent versatility and stability and is useful as a protecting reagent (anchor) for an amino acid and/or a peptide in the liquid-phase synthesis or the like of a peptide with a carboxamide (-CONHR) a...  
WO2010110142A1
Disclosed is a process for producing a urethane compound, which comprises reacting a primary amine, either urea and/or an N-unsubstituted carbamic acid ester, and an alcohol with one another in the presence of a compound containing a non...  
WO/2010/105768A1
The invention is directed to a process for preparing aromatic carbamates which comprises the reaction of an aromatic amine with an organic carbonate in the presence of a catalyst characterized in that Zn4O(OAc)6 is used as catalyst.  
WO/2010/105761A1
A process for the preparation in high yields and purity of the compound 6-(7-((l-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy )-N-methyl- 1 -naphthamide of formula (I) and of the pharmaceutically acceptable salts thereof is descri...  
WO/2010/102747A2
Disclosed are new compounds having utility in applications, including as reactants and intermediates in for the formation of polymers and polymeric materials especially useful as hydrogels for ophthalmic lenses.  
WO/2010/104082A1
A novel polyimide precursor or polyimide which can give a liquid-crystal alignment film having a low volume resistivity, a liquid-crystal alignment material comprising either of these polymers, a liquid-crystal alignment film, and a nove...  
WO/2010/104106A1
Disclosed is a method for industrially producing compound (1) and compound (4) to provide an important intermediate for producing an FXa inhibitor. Specifically disclosed is a production method characterized by comprising: a first step o...  
WO/2010/099745A1
Preparation methods of rivastigmine tartrate and its intermediate and the intermediate itself are disclosed. More specifically, the intermediate compound [1-(3-benzyloxy-phenyl)-ethyl]-dimethylamine, its preparation method and methods fo...  
WO/2010/098193A1
Optically active β-aminocarbonyl compounds are obtained by a Mannich reaction of an optically active binaphthol represented by formula (1a), (1b), (2a) or (2b) (in each formula, Ar1 is a phenyl group wherein hydrogen atoms are bound to ...  

Matches 651 - 700 out of 7,730